Toll Free: 1-888-928-9744

Renal Cell Carcinoma - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 811 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Renal Cell Carcinoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Renal Cell Carcinoma - Pipeline Review, H1 2016', provides an overview of the Renal Cell Carcinoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Renal Cell Carcinoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma
- The report reviews pipeline therapeutics for Renal Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Renal Cell Carcinoma therapeutics and enlists all their major and minor projects
- The report assesses Renal Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Renal Cell Carcinoma

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 7 Renal Cell Carcinoma Overview 8 Therapeutics Development 9 Renal Cell Carcinoma - Therapeutics under Development by Companies 11 Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 19 Renal Cell Carcinoma - Pipeline Products Glance 20 Renal Cell Carcinoma - Products under Development by Companies 24 Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 34 Renal Cell Carcinoma - Companies Involved in Therapeutics Development 35 Renal Cell Carcinoma - Therapeutics Assessment 129 Drug Profiles 157 Renal Cell Carcinoma - Recent Pipeline Updates 479 Renal Cell Carcinoma - Dormant Projects 765 Renal Cell Carcinoma - Discontinued Products 779 Renal Cell Carcinoma - Product Development Milestones 783 Appendix 794
List of Tables
Number of Products under Development for Renal Cell Carcinoma, H1 2016 25 Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H1 2016 26 Number of Products under Development by Companies, H1 2016 28 Number of Products under Development by Companies, H1 2016 (Contd..1) 29 Number of Products under Development by Companies, H1 2016 (Contd..2) 30 Number of Products under Development by Companies, H1 2016 (Contd..3) 31 Number of Products under Development by Companies, H1 2016 (Contd..4) 32 Number of Products under Development by Companies, H1 2016 (Contd..5) 33 Number of Products under Development by Companies, H1 2016 (Contd..6) 34 Number of Products under Investigation by Universities/Institutes, H1 2016 35 Comparative Analysis by Late Stage Development, H1 2016 36 Comparative Analysis by Clinical Stage Development, H1 2016 37 Comparative Analysis by Early Stage Development, H1 2016 38 Comparative Analysis by Unknown Stage Development, H1 2016 39 Products under Development by Companies, H1 2016 40 Products under Development by Companies, H1 2016 (Contd..1) 41 Products under Development by Companies, H1 2016 (Contd..2) 42 Products under Development by Companies, H1 2016 (Contd..3) 43 Products under Development by Companies, H1 2016 (Contd..4) 44 Products under Development by Companies, H1 2016 (Contd..5) 45 Products under Development by Companies, H1 2016 (Contd..6) 46 Products under Development by Companies, H1 2016 (Contd..7) 47 Products under Development by Companies, H1 2016 (Contd..8) 48 Products under Development by Companies, H1 2016 (Contd..9) 49 Products under Investigation by Universities/Institutes, H1 2016 50 Renal Cell Carcinoma - Pipeline by AbbVie Inc., H1 2016 51 Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H1 2016 52 Renal Cell Carcinoma - Pipeline by Advenchen Laboratories, LLC, H1 2016 53 Renal Cell Carcinoma - Pipeline by Altor BioScience Corporation, H1 2016 54 Renal Cell Carcinoma - Pipeline by Ambrx, Inc., H1 2016 55 Renal Cell Carcinoma - Pipeline by Amgen Inc., H1 2016 56 Renal Cell Carcinoma - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 57 Renal Cell Carcinoma - Pipeline by arGEN-X BV, H1 2016 58 Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H1 2016 59 Renal Cell Carcinoma - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016 60 Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H1 2016 61 Renal Cell Carcinoma - Pipeline by Bayer AG, H1 2016 62 Renal Cell Carcinoma - Pipeline by Beta Pharma, Inc., H1 2016 63 Renal Cell Carcinoma - Pipeline by Bio-Cancer Treatment International Limited, H1 2016 64 Renal Cell Carcinoma - Pipeline by BIOCAD, H1 2016 65 Renal Cell Carcinoma - Pipeline by Bionomics Limited, H1 2016 66 Renal Cell Carcinoma - Pipeline by Bionovis SA, H1 2016 67 Renal Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 68 Renal Cell Carcinoma - Pipeline by Boston Biomedical, Inc., H1 2016 69 Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 70 Renal Cell Carcinoma - Pipeline by Caladrius Biosciences, Inc. , H1 2016 71 Renal Cell Carcinoma - Pipeline by Calithera Biosciences, Inc., H1 2016 72 Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H1 2016 73 Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 74 Renal Cell Carcinoma - Pipeline by Celltrion, Inc., H1 2016 75 Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H1 2016 76 Renal Cell Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H1 2016 77 Renal Cell Carcinoma - Pipeline by Cytune Pharma SAS, H1 2016 78 Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 79 Renal Cell Carcinoma - Pipeline by EirGenix Inc., H1 2016 80 Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H1 2016 81 Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H1 2016 82 Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H1 2016 83 Renal Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 84 Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H1 2016 85 Renal Cell Carcinoma - Pipeline by GenSpera, Inc., H1 2016 86 Renal Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H1 2016 87 Renal Cell Carcinoma - Pipeline by Horizon Pharma Plc, H1 2016 88 Renal Cell Carcinoma - Pipeline by Hutchison MediPharma Limited, H1 2016 89 Renal Cell Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H1 2016 90 Renal Cell Carcinoma - Pipeline by Immune Design Corp., H1 2016 91 Renal Cell Carcinoma - Pipeline by Immunicum AB, H1 2016 92 Renal Cell Carcinoma - Pipeline by ImmunoGen, Inc., H1 2016 93 Renal Cell Carcinoma - Pipeline by Incuron, LLC, H1 2016 94 Renal Cell Carcinoma - Pipeline by Incyte Corporation, H1 2016 95 Renal Cell Carcinoma - Pipeline by KAHR medical Ltd., H1 2016 96 Renal Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 97 Renal Cell Carcinoma - Pipeline by KineMed, Inc., H1 2016 98 Renal Cell Carcinoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 99 Renal Cell Carcinoma - Pipeline by Lead Discovery Center GmbH, H1 2016 100 Renal Cell Carcinoma - Pipeline by Mabion SA, H1 2016 101 Renal Cell Carcinoma - Pipeline by MacroGenics, Inc., H1 2016 102 Renal Cell Carcinoma - Pipeline by MediaPharma s.r.l., H1 2016 103 Renal Cell Carcinoma - Pipeline by MedImmune, LLC, H1 2016 104 Renal Cell Carcinoma - Pipeline by Medivation, Inc., H1 2016 105 Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H1 2016 106 Renal Cell Carcinoma - Pipeline by Merck KGaA, H1 2016 107 Renal Cell Carcinoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 108 Renal Cell Carcinoma - Pipeline by Mirna Therapeutics, Inc., H1 2016 109 Renal Cell Carcinoma - Pipeline by Molecular Partners AG, H1 2016 110 Renal Cell Carcinoma - Pipeline by Mologen AG, H1 2016 111 Renal Cell Carcinoma - Pipeline by Monopar Therapeutics LLC, H1 2016 112 Renal Cell Carcinoma - Pipeline by Mycenax Biotech Inc., H1 2016 113 Renal Cell Carcinoma - Pipeline by Nektar Therapeutics, H1 2016 114 Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H1 2016 115 Renal Cell Carcinoma - Pipeline by Novartis AG, H1 2016 116 Renal Cell Carcinoma - Pipeline by NovaTarg Therapeutics, Inc, H1 2016 117 Renal Cell Carcinoma - Pipeline by Omeros Corporation, H1 2016 118 Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H1 2016 119 Renal Cell Carcinoma - Pipeline by OncoMax, H1 2016 120 Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 121 Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H1 2016 122 Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H1 2016 123 Renal Cell Carcinoma - Pipeline by Pfizer Inc., H1 2016 124 Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H1 2016 125 Renal Cell Carcinoma - Pipeline by PsiOxus Therapeutics Limited, H1 2016 126 Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016 127 Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H1 2016 128 Renal Cell Carcinoma - Pipeline by Sevion Therapeutics, Inc., H1 2016 129 Renal Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H1 2016 130 Renal Cell Carcinoma - Pipeline by Sorrento Therapeutics, Inc., H1 2016 131 Renal Cell Carcinoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 132 Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016 133 Renal Cell Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 134 Renal Cell Carcinoma - Pipeline by TC BioPharm Limited, H1 2016 135 Renal Cell Carcinoma - Pipeline by Theravectys SA, H1 2016 136 Renal Cell Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 137 Renal Cell Carcinoma - Pipeline by Tocagen Inc., H1 2016 138 Renal Cell Carcinoma - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016 139 Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H1 2016 140 Renal Cell Carcinoma - Pipeline by Tyrogenex, Inc., H1 2016 141 Renal Cell Carcinoma - Pipeline by Vascular Biogenics Ltd., H1 2016 142 Renal Cell Carcinoma - Pipeline by ViiV Healthcare Limited, H1 2016 143 Renal Cell Carcinoma - Pipeline by X4 Pharmaceuticals, Inc., H1 2016 144 Assessment by Monotherapy Products, H1 2016 145 Assessment by Combination Products, H1 2016 146 Number of Products by Stage and Target, H1 2016 148 Number of Products by Stage and Mechanism of Action, H1 2016 161 Number of Products by Stage and Route of Administration, H1 2016 170 Number of Products by Stage and Molecule Type, H1 2016 172 Renal Cell Carcinoma Therapeutics - Recent Pipeline Updates, H1 2016 495 Renal Cell Carcinoma - Dormant Projects, H1 2016 781 Renal Cell Carcinoma - Dormant Projects (Contd..1), H1 2016 782 Renal Cell Carcinoma - Dormant Projects (Contd..2), H1 2016 783 Renal Cell Carcinoma - Dormant Projects (Contd..3), H1 2016 784 Renal Cell Carcinoma - Dormant Projects (Contd..4), H1 2016 785 Renal Cell Carcinoma - Dormant Projects (Contd..5), H1 2016 786 Renal Cell Carcinoma - Dormant Projects (Contd..6), H1 2016 787 Renal Cell Carcinoma - Dormant Projects (Contd..7), H1 2016 788 Renal Cell Carcinoma - Dormant Projects (Contd..8), H1 2016 789 Renal Cell Carcinoma - Dormant Projects (Contd..9), H1 2016 790 Renal Cell Carcinoma - Dormant Projects (Contd..10), H1 2016 791 Renal Cell Carcinoma - Dormant Projects (Contd..11), H1 2016 792 Renal Cell Carcinoma - Dormant Projects (Contd..12), H1 2016 793 Renal Cell Carcinoma - Dormant Projects (Contd..13), H1 2016 794 Renal Cell Carcinoma - Discontinued Products, H1 2016 795 Renal Cell Carcinoma - Discontinued Products (Contd..1), H1 2016 796 Renal Cell Carcinoma - Discontinued Products (Contd..2), H1 2016 797 Renal Cell Carcinoma - Discontinued Products (Contd..3), H1 2016 798


List of Figures
Number of Products under Development for Renal Cell Carcinoma, H1 2016 25 Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H1 2016 26 Number of Products under Development by Companies, H1 2016 27 Number of Products under Investigation by Universities/Institutes, H1 2016 35 Comparative Analysis by Late Stage Development, H1 2016 36 Comparative Analysis by Clinical Stage Development, H1 2016 37 Comparative Analysis by Early Stage Products, H1 2016 38 Assessment by Monotherapy Products, H1 2016 145 Assessment by Combination Products, H1 2016 146 Number of Products by Top 10 Targets, H1 2016 147 Number of Products by Stage and Top 10 Targets, H1 2016 147 Number of Products by Top 10 Mechanism of Actions, H1 2016 160 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 160 Number of Products by Top 10 Routes of Administration, H1 2016 169 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 169 Number of Products by Top 10 Molecule Types, H1 2016 171 Number of Products by Stage and Top 10 Molecule Types, H1 2016 171

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global microcontroller market is estimated to be valued at USD 26.9 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing demand in key application areas such as automotive, consumer electronics and healthcare is expected to

Read More...

Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global dem

Read More...

Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to dri

Read More...

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify